Cellectis - ADR
CLLS
Get informed when a big investor buys or sells
+ FollowMarket Cap$111.22M
Close$
$-1.33
220.6% downside
Current Fair Value
220.6% downsideOvervalued by 220.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $111.22 Million |
|---|---|
| Enterprise Value | $251.14 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.68 |
| Beta | 3 |
| Outstanding Shares | 100,647,451 |
Return
| Return on Equity | -159.71% |
|---|---|
| Return on Assets | -24.53% |
| Return on Invested Capital | -37.36% |
Valuation & Multiples
| P/E Ratio | -1.93 |
|---|---|
| PEG | 20.96 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.44 |
| Enterprise Value to EBIT | -5.08 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.7 |
| Debt to Equity | 4.27 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.26
Average shareholder expectationRevenue Estimate
$11.05 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
$15.19 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 9.42%▼ 0.78% |
|---|---|
| Total Invested | $28.45M▼ 12.52% |
| Investors Holding | 27▼ 6.00% |
ESG Score
No data
About Cellectis
227 employees
CEO: Andre Choulika Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to dis...